Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer

BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis. AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017. METHODS: The monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollina, Uwe, Tchernev, Georgi, Lotti, Torello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816291/
https://www.ncbi.nlm.nih.gov/pubmed/29484016
http://dx.doi.org/10.3889/oamjms.2018.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816291/
https://www.ncbi.nlm.nih.gov/pubmed/29484016
http://dx.doi.org/10.3889/oamjms.2018.022

Ejemplares similares